Fixed-dose combination pen containing both cagrilintide and semaglutide
PubMed, Zeng, Shuangshuang, et al
Cardiovascular calcification: artificial intelligence and big data accelerate mechanistic discovery
Types of diabetes and PDAC risk Diabetes describes a collection of metabolic disorders that disrupts the bodys ability to regulate glucose levels due to dysfunction in insulin secretion by pancreatic -cells, uptake of insulin at insulin-dependent tissues, or both ( Figure 2 ) ( Figure 2 Type 1 diabetes mellitus (T1D) is an autoimmune disorder that accounts for 5-10% of cases of diabetes ( Figure 2 ) ( Figure 2 ) ( Type 2 diabetes mellitus (T2D) accounts for 90-95% of all diabetes that occurs due to relative insulin deficiency and insulin resistance at peripheral tissues, resulting in chronically elevated blood glucose levels ( Figure 2 ) ( Type 3c Diabetes (T3cD), also known as pancreatogenic diabetes occurs secondary to an injury of the exocrine pancreas that results in the loss of insulin secretion for glucose homeostasis ( Figure 2 ) ( Figure 2 )
Novo Nordisk revealed in April 2024, that to meet the enormous demand for semaglutide, it was running its production facilities 24/7
Experimental evidence supporting extrinsic Fas-mediated eryptosis suggests that eryptosis can be induced by external perturbations
